Clinical Trials Directory

Trials / Completed

CompletedNCT05077189

Temporomandibular Joint and COVID-19

Temporomandibular Joint Complains in Patients With COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
76 (actual)
Sponsor
Recep Tayyip Erdogan University Training and Research Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

There is evidence that CV-19 is associated with joint symptoms, but there are no specific data on the temporomandibular joint (TMJ). It is also known that the systemic health status can impact the immune system. Given all this, this study aimed to investigate the effect of CV-19 and systemic health status, as determined by the American Society of Anesthesiologists (ASA) Physical Status Classification System 12, on TMJ in patients with TMJ complaints using the DC/TMD scale.

Detailed description

This study investigates the effect of systemic status, according to American Society of Anesthesiologist (ASA), and COVID-19 on temporomandibular joint (TMJ) disorders using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale, shown to be valid for assessing TMJ disorders. The study included 76 patients who presented to our clinic with TMJ. Participants were divided into two groups: those with COVID-19 (CV-19, study group) and those without (non-CV-19, control group). These two groups were both further divided into subgroups according to ASA 1 and ASA 2 classification. Power analyses were performed using G\*Power software to determine the required number of patients. Groups were compared using the Symptom Questionnaire, a demographics survey, the Graded Chronic Pain Scale (GCPS), and the Jaw Functional Limitation Scale-20 (JFLS-20) of the DC/TMD. The statistical software program version 1.6.23 was used for statistical analysis. Although joint complaints were more common in ASA 2 patients with CV-19, the groups were not significantly different. The CV-19 ASA 2 group had the highest JFLS-20 score (mean: 1.3±1.5) and the non-CV-19 ASA 1 group had the lowest JFLS-20 score (mean: 0.7±0.8), but the differences were again not significant. Joint complaints were more common and more severe in ASA 2 patients with CV-19, albeit not with statistical significance. More studies are needed to better understand our results.

Conditions

Interventions

TypeNameDescription
OTHERDiagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders. 1. Demographics Survey 2. DC/TMD Symptom Questionnaire (SQ) 3. Graded Chronic Pain Scale (GCPS) 4. Jaw Functional Limitation Scale-20 (JFLS-20)

Timeline

Start date
2020-12-01
Primary completion
2021-03-01
Completion
2021-06-01
First posted
2021-10-14
Last updated
2021-10-21

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05077189. Inclusion in this directory is not an endorsement.